Enter

EN

TW
EN

About UBIP
Technology Platform
RD & Products
Quality
CMO/CDMO Services
- Tailored Solutions
- Facility & Capacity
News
- Press Release
- Media Coverage
Contact us

Search

TW EN

News

Press Release
- Our company's new compound drug NDF01 for the treatment of HIV infection has been approved by the Ministry of Health and Welfare
- The sterile vial line-2 of UBIP's expanded factory passed the GMP inspection of the Ministry of Health and Welfare.
- Employee Travel Leave Notice
- Explanation of UBI Pharma's cessation of stock trading on the Taipei Exchange and the current operational status of the company
- UBI Pharma announces its participation in the '2024 TALENT, in Taiwan' alliance for sustainable talent development in Taiwan."
- UBI Pharma's explanation for the termination of stock trading on the Taipei Exchange
- UBI Pharma passes GMP inspection by the UK MHRA.
- UBI Pharma applies to the Taiwan Food and Drug Administration (TFDA) for drug inspection registration of the biosimilar drug erythropoietin UB-851.
- UBI Pharma passes GMP inspection by Japan's Pharmaceuticals and Medical Devices Agency (PMDA).
- UBI Pharma obtains a US patent certificate for the "Single-Chain Immunoglobulin Fusion Protein Technology Platform."
- UBI Pharma applies to the TFDA for drug inspection registration of the new compound drug NDF01 for the treatment of HIV infection.
- UBI Pharma signs an investment and exclusive licensing sales agreement with Ory Biotech Co., Ltd. for the bio-similar drug UB-851.
- UBI Pharma's Hsinchu plant receives formal Establishment Inspection Report (EIR) approval from the United States Food and Drug Administration (FDA).
- UBI Pharma's proprietary product, Voriconazole Injection, has received approval for Abbreviated New Drug Application (ANDA) from the United States.
- UBI Pharma Inc. responds to community greening and carbon reduction tree planting activities
- UBI Pharma Inc. Achieves Another Milestone in the US Market: Its Anti-Fungal Injection Generic Product Approved by the US FDA
- UBI Pharma Inc. Expands Southeast Asian Market: Epilepsy Drug Levetiracetam Was Approved in Malaysia
- Bioequivalence Study is Completed for UBIP’s New Formulation New Drug NDF01, and Will Proceed to NDA Filing Soon
- UBI Pharma Inc. passed the TTQS(Talent Quality-management System) assessment and received the bronze medal
- The Clinical Study Report of the Phase III Clinical Trial of UBIP’s Recombinant Human Erythropoietin Biosimilar Drug UB-851 Has Been Completed
- The Production Line of UBI Pharma Inc. for Manufacturing Sterile Injectable Drugs Has Been Approved by the U.S. Food and Drug Administration

Media Coverage
- The UK's MHRA has cleared UBI's COVID-19 vaccine, UB-612, after inspecting its manufacturing facility. UBIP's production base in Taiwan has obtained GMP certification!
- UBIP has completed the submission for its in-house developed biosimilar drug (UB-851, EPO) to TFDA
- UBI Pharma Inc.'s "Single-Chain Immunoglobulin Fusion Protein Technology" has been granted a patent in the USA
- Merdury Biopharmaceutical Corporation Partners with UBI Pharma Inc. to Pioneer Sildenafil Orally Disintegrating Tablets for the $4.5 Billion Global ED Drug Market
- UBI Pharma Inc. as received two prestigious awards at the 20th National Brand Yushan Awards (2023)
- UBI Pharma Inc. has commissioned EirGenix to produce the biosimilar drug UB-851, paving the way for an early international market expansion.
- UBI Pharma Inc. Passes Ukrainian Inspection, Joining Lumosa Therapeutics to Enter European Market
- The Phase III Trial of the EPO Injection Developed by UBI Pharma Inc. has been Completed, the Company Plans to Submit an Application for Drug Licensing to the TFDA
- Successful Unblinding of the Phase III Clinical Trial of Erythropoietin Conducted by UBI Pharma Inc.
- The Unique Long-acting Technology Platform Developed by UBI Pharma Inc. Has Been Granted a Patent by the United States and Canada
- TFDA Approves the Phase I Clinical Trial of the New Drug UB-852 Developed by UBI Pharma Inc.
- TFDA Approves the Phase I Clinical Trial of the New Targeted Anticancer Drug UB-941 Developed by UBI Pharma Inc.

Events

Home
News
Press Release
UBI Pharma's explanation for the termination of stock trading on the Taipei Exchange

UBI Pharma's explanation for the termination of stock trading on the Taipei Exchange

2024-05-03

UBI Pharma Inc.

TEL +886-3-5977676
FAX +886-3-5981173
Address No.45, Guangfu N. Rd., Hukou Township, Hsinchu County 303036, Taiwan (R.O.C.)

Adverse Reaction Contact
24 hour phone +886-800-035-511
email pharmacovigilance@ubi-pharma.com

Privacy Policy